Found 128 with Last Name = 'choe' and Initial = 'sa' 
Affinity DataKi: 0.25nMAssay Description:Displacement of [125I]I-AB-MECA from human adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
Affinity DataKi: 0.330nMAssay Description:Displacement of [125I]I-AB-MECA from rat adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
Affinity DataKi: 0.380nMAssay Description:Displacement of [125I]I-AB-MECA from human adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
Affinity DataKi: 0.380nMAssay Description:Displacement of [3H]I-AB-MECA from human recombinant adenosine A3 receptor expressed in CHO cells by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 0.380nMAssay Description:Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
Affinity DataKi: 0.820nMAssay Description:Displacement of [125I]I-AB-MECA from rat adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
Affinity DataKi: 1nMAssay Description:Displacement of [125I]I-AB-MECA from human adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
Affinity DataKi: 1.10nMAssay Description:Displacement of [125I]I-AB-MECA from rat adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
Affinity DataKi: 1.40nMAssay Description:Displacement of [125I]I-AB-MECA from human adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
Affinity DataKi: 1.40nMAssay Description:Displacement of [3H]I-AB-MECA from human recombinant adenosine A3 receptor expressed in CHO cells by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 1.40nMAssay Description:Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
Affinity DataKi: 1.5nMAssay Description:Displacement of [125I]I-AB-MECA from human adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
TargetAdenosine receptor A2a(Homo sapiens (Human))
FM Therapeutics Co., Ltd.; The United States of America, As Represented by the Secretary, Department of Health and Human Services, The Office of Technology Transfer, National Institutes of Health
US Patent
FM Therapeutics Co., Ltd.; The United States of America, As Represented by the Secretary, Department of Health and Human Services, The Office of Technology Transfer, National Institutes of Health
US Patent
Affinity DataKi: 1.5nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
TargetAdenosine receptor A2a(Homo sapiens (Human))
FM Therapeutics Co., Ltd.; The United States of America, As Represented by the Secretary, Department of Health and Human Services, The Office of Technology Transfer, National Institutes of Health
US Patent
FM Therapeutics Co., Ltd.; The United States of America, As Represented by the Secretary, Department of Health and Human Services, The Office of Technology Transfer, National Institutes of Health
US Patent
Affinity DataKi: 1.66nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
Affinity DataKi: 1.66nMAssay Description:Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
Affinity DataKi: 1.86nMAssay Description:Displacement of [125I]I-AB-MECA from rat adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
Affinity DataKi: 2.5nMAssay Description:Displacement of [125I]I-AB-MECA from human adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
TargetAdenosine receptor A2a(Homo sapiens (Human))
FM Therapeutics Co., Ltd.; The United States of America, As Represented by the Secretary, Department of Health and Human Services, The Office of Technology Transfer, National Institutes of Health
US Patent
FM Therapeutics Co., Ltd.; The United States of America, As Represented by the Secretary, Department of Health and Human Services, The Office of Technology Transfer, National Institutes of Health
US Patent
Affinity DataKi: 2.5nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
TargetAdenosine receptor A2a(Homo sapiens (Human))
FM Therapeutics Co., Ltd.; The United States of America, As Represented by the Secretary, Department of Health and Human Services, The Office of Technology Transfer, National Institutes of Health
US Patent
FM Therapeutics Co., Ltd.; The United States of America, As Represented by the Secretary, Department of Health and Human Services, The Office of Technology Transfer, National Institutes of Health
US Patent
Affinity DataKi: 3.69nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
Affinity DataKi: 3.69nMAssay Description:Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
Affinity DataKi: 4.16nMAssay Description:Displacement of [3H]I-AB-MECA from human recombinant adenosine A3 receptor expressed in CHO cells by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 4.16nMAssay Description:Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
TargetAdenosine receptor A2a(Homo sapiens (Human))
FM Therapeutics Co., Ltd.; The United States of America, As Represented by the Secretary, Department of Health and Human Services, The Office of Technology Transfer, National Institutes of Health
US Patent
FM Therapeutics Co., Ltd.; The United States of America, As Represented by the Secretary, Department of Health and Human Services, The Office of Technology Transfer, National Institutes of Health
US Patent
Affinity DataKi: 4.16nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
Affinity DataKi: 4.80nMAssay Description:Displacement of [125I]I-AB-MECA from human adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
Affinity DataKi: 6.10nMAssay Description:Displacement of [125I]I-AB-MECA from human adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
Affinity DataKi: 6.20nMAssay Description:Displacement of [125I]I-AB-MECA from human adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
Affinity DataKi: 6.30nMAssay Description:Displacement of [125I]I-AB-MECA from rat adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
Affinity DataKi: 6.80nMAssay Description:Displacement of [125I]I-AB-MECA from human adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
TargetAdenosine receptor A2a(Homo sapiens (Human))
FM Therapeutics Co., Ltd.; The United States of America, As Represented by the Secretary, Department of Health and Human Services, The Office of Technology Transfer, National Institutes of Health
US Patent
FM Therapeutics Co., Ltd.; The United States of America, As Represented by the Secretary, Department of Health and Human Services, The Office of Technology Transfer, National Institutes of Health
US Patent
Affinity DataKi: 6.80nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
Affinity DataKi: 7.30nMAssay Description:Displacement of [125I]I-AB-MECA from human adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
TargetAdenosine receptor A2a(Homo sapiens (Human))
FM Therapeutics Co., Ltd.; The United States of America, As Represented by the Secretary, Department of Health and Human Services, The Office of Technology Transfer, National Institutes of Health
US Patent
FM Therapeutics Co., Ltd.; The United States of America, As Represented by the Secretary, Department of Health and Human Services, The Office of Technology Transfer, National Institutes of Health
US Patent
Affinity DataKi: 7.30nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
Affinity DataKi: 7.40nMAssay Description:Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
TargetAdenosine receptor A2a(Homo sapiens (Human))
FM Therapeutics Co., Ltd.; The United States of America, As Represented by the Secretary, Department of Health and Human Services, The Office of Technology Transfer, National Institutes of Health
US Patent
FM Therapeutics Co., Ltd.; The United States of America, As Represented by the Secretary, Department of Health and Human Services, The Office of Technology Transfer, National Institutes of Health
US Patent
Affinity DataKi: 7.40nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
TargetAdenosine receptor A2a(Homo sapiens (Human))
FM Therapeutics Co., Ltd.; The United States of America, As Represented by the Secretary, Department of Health and Human Services, The Office of Technology Transfer, National Institutes of Health
US Patent
FM Therapeutics Co., Ltd.; The United States of America, As Represented by the Secretary, Department of Health and Human Services, The Office of Technology Transfer, National Institutes of Health
US Patent
Affinity DataKi: 8.99nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
Affinity DataKi: 8.99nMAssay Description:Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
TargetAdenosine receptor A2a(Homo sapiens (Human))
FM Therapeutics Co., Ltd.; The United States of America, As Represented by the Secretary, Department of Health and Human Services, The Office of Technology Transfer, National Institutes of Health
US Patent
FM Therapeutics Co., Ltd.; The United States of America, As Represented by the Secretary, Department of Health and Human Services, The Office of Technology Transfer, National Institutes of Health
US Patent
Affinity DataKi: 12.7nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
Affinity DataKi: 12.7nMAssay Description:Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
TargetAdenosine receptor A2a(Homo sapiens (Human))
FM Therapeutics Co., Ltd.; The United States of America, As Represented by the Secretary, Department of Health and Human Services, The Office of Technology Transfer, National Institutes of Health
US Patent
FM Therapeutics Co., Ltd.; The United States of America, As Represented by the Secretary, Department of Health and Human Services, The Office of Technology Transfer, National Institutes of Health
US Patent
Affinity DataKi: 13nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
Affinity DataKi: 13nMAssay Description:Displacement of [3H]I-AB-MECA from human recombinant adenosine A3 receptor expressed in CHO cells by liquid scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 15.5nMAssay Description:Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
Affinity DataKi: 15.5nMAssay Description:Displacement of [125I]I-AB-MECA from human adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
Affinity DataKi: 17nMAssay Description:Displacement of [125I]I-AB-MECA from rat adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
Affinity DataKi: 17.3nMAssay Description:Displacement of [3H]CCPA from human adenosine A1 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
Affinity DataKi: 19.9nMAssay Description:Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
TargetAdenosine receptor A2a(Homo sapiens (Human))
FM Therapeutics Co., Ltd.; The United States of America, As Represented by the Secretary, Department of Health and Human Services, The Office of Technology Transfer, National Institutes of Health
US Patent
FM Therapeutics Co., Ltd.; The United States of America, As Represented by the Secretary, Department of Health and Human Services, The Office of Technology Transfer, National Institutes of Health
US Patent
Affinity DataKi: 19.9nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
Affinity DataKi: 24.8nMAssay Description:Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
TargetAdenosine receptor A2a(Homo sapiens (Human))
FM Therapeutics Co., Ltd.; The United States of America, As Represented by the Secretary, Department of Health and Human Services, The Office of Technology Transfer, National Institutes of Health
US Patent
FM Therapeutics Co., Ltd.; The United States of America, As Represented by the Secretary, Department of Health and Human Services, The Office of Technology Transfer, National Institutes of Health
US Patent
Affinity DataKi: 24.8nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
Affinity DataKi: 25.8nMAssay Description:Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
TargetAdenosine receptor A2a(Homo sapiens (Human))
FM Therapeutics Co., Ltd.; The United States of America, As Represented by the Secretary, Department of Health and Human Services, The Office of Technology Transfer, National Institutes of Health
US Patent
FM Therapeutics Co., Ltd.; The United States of America, As Represented by the Secretary, Department of Health and Human Services, The Office of Technology Transfer, National Institutes of Health
US Patent
Affinity DataKi: 25.8nMAssay Description:CHO cells (ATCC No. CCL-61), in which A1 and A3 adenosine receptors were expressed, were cultured in F-12 media (Gibco, U.S.A.) supplemented with 10%...More data for this Ligand-Target Pair
Affinity DataKi: 29nMAssay Description:Displacement of [125I]AB-MECA from human adenosine A3 receptor expressed in CHO cellsMore data for this Ligand-Target Pair
